title: Deletion analysis of p16(INKa) and p15(INKb) in relapsed childhood acute lymphoblastic leukemia.
abstract: This study aimed at determining the prevalence of INK4 deletions and their impact on outcome in 125 children with acute lymphoblastic leukemia (ALL) at first relapse using real-time quantitative polymerase chain reaction. Patients were enrolled into relapse trials ALL-REZ BFM (ALL-Relapse Berlin-Frankfurt-Münster) 90 and 96. The prevalence of p16(INK4a) and p15(INK4b) homozygous deletions was 35% (44 of 125) and 30% (38 of 125), respectively. A highly significant association of both gene deletions was found with the 2 major adverse prognostic factors known for relapsed childhood ALL: T-cell immunophenotype and first remission duration. There was no correlation between INK4 deletions and probability of event-free survival. These findings argue against an independent prognostic role of INK4 deletions in relapsed childhood ALL.
authors.affiliation: Department of Pediatric Oncology/Hematology, Charité Medical Center, Campus Virchow-Klinikum, Humboldt University of Berlin, Germany. hagenve@@charite.de
authors.forename: Hagen
authors.initials: H
authors.lastname: Graf Einsiedel
authors.forename: Tillmann
authors.initials: T
authors.lastname: Taube
authors.forename: Reinhard
authors.initials: R
authors.lastname: Hartmann
authors.forename: Sven
authors.initials: S
authors.lastname: Wellmann
authors.forename: Georg
authors.initials: G
authors.lastname: Seifert
authors.forename: Günter
authors.initials: G
authors.lastname: Henze
authors.forename: Karl
authors.initials: K
authors.lastname: Seeger
mesh_terms: D001854:Bone Marrow Cells / Q000473:pathology; D018797:Cell Cycle Proteins / Q000235:genetics*; D002648:Child; D050762:Cyclin-Dependent Kinase Inhibitor p15; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000235:genetics*; D018572:Disease-Free Survival; D005260:Female; D017353:Gene Deletion; D006801:Humans; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000453:epidemiology / Q000235:genetics* / Q000473:pathology; D015995:Prevalence; D011379:Prognosis; D012008:Recurrence; D012189:Retrospective Studies; D016019:Survival Analysis; D025521:Tumor Suppressor Proteins
chemical_list: C493966:CDKN2B protein, human; D018797:Cell Cycle Proteins; D050762:Cyclin-Dependent Kinase Inhibitor p15; D019941:Cyclin-Dependent Kinase Inhibitor p16; D025521:Tumor Suppressor Proteins